92.9% Think Polymorphism and Crystallisation is the Greatest Challenge They Face
Polymorphism and crystallisation are considered to be one of the most significant and demanding areas of pharmaceutical development. New discoveries have the potential to either give organisations a share of a crowded market place to great financial and reputational benefit or have hugely damaging repercussions, depending on at what stage the alternative crystallisation formation was discovered.
However, with the swift leaps and bounds in technology development and quality by design processes, organisations are also faced with the challenge of keeping up to date with the latest research in order to stay at the forefront of the industry, as well as improve safety, best practice and the efficacy of drugs.
|
|
|
Have Your Say Rate this feature and give us your feedback in the comments section below |
Tags: polymorphism | crystallisation | drug development | Quality by Design
-
International Conference PLM in Pharmaceutical & Biotechnical Development
Dorint Hotel Sanssouci Berlin-Potsdam
May 21- 23, 2012 -
Global Formulation and Drug Delivery Summit 2012
Park Hotel Amsterdam, Netherlands
April 16- 18, 2012 -
4th Clinical Trials Supply & Logistics Summit
San Francisco, CA
June 25- 27, 2012 -
Software Design for Medical Devices
The HUB Commerce Square, Philadelphia, PA
May 21- 23, 2012
-
Keeping Your Supply Chain Competitive: Priorities for 2011
Paul Wiberg-Jørgensen, VP Logistics, Statens Serum Institut, speaks with Andrea Charles from Pharma
Pharma IQ
-
Critical Success Factors for S&OP
In this quick-fire Q&A Dr. Christian Borel, Director Sales & Operations Planning Process, Supply... Read more
Christian Borel






Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!